At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Chemotherapy Combined with Immune Checkpoint Inhibitors in Patients with ALK-rearranged Non-small Cell Lung Cancer (NSCLC) Who Have Progressed After First-line Alectinib: a Proof-of-concept, Phase 2 Trial
In Brief
A Phase 2 clinical trial evaluating Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab and Chemotherapy alone or Chemotherapy with or without Bevacizumab for Non-small Cell Lung Cancer. Completed, enrolled 112 participants across 1 site.
Detailed Summary
This study aimed to investigate the combination of chemotherapy and immunotherapy for patients with metastatic ALK fusion-positive non-small cell lung cancer (NSCLC) who had failed from first line Alectinib. Additionally, available biological samples such as blood and tumor tissues were collected to explore potential biomarkers, including but not limited to RNA-seq, whole-exome sequencing (WES), whole-genome sequencing (WGS), immunohistochemistry, and multiplex immunofluorescence.
Study Details
Timeline
Interventions
Immune Checkpoint Inhibitors, for pembrolizumab, 200mg ivgtt once,every 21 days; for Atezolizumab, 1200mg vgtt once,every 21 days.
Bevacizumab, 15mg/kg，every 21 day